π¬ Breast Cancer Intelligence Digest β Week 2026-W38
SERENA-4 is negative for camizestrant plus palbociclib in the first line while camizestrant wins accelerated approval for ESR1 emergence, a 2801-patient Japanese analysis quantifies T-DXd ILD at 14% with 7.9% fatal, and pinned papers deliver trastuzumab botidotin PFS 11.1 vs 4.4 months over T-DM1, iza-bren phase 1b activity across all three breast subtypes, HLX11 pertuzumab biosimilar equivalence, and an ADC PFS/OS surrogacy meta-analysis.
β‘ TL;DR
π Publications
- Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer. β Randomized data indicate carboplatin can be safely omitted from neoadjuvant therapy for most patients with stage II HER2-positive early breast cancer, with comparable pathological complete response rates and reduced toxicity
- Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial. β 908 patients were randomized 1:1 to HLX11 (n=454) or EU-pertuzumab (n=454) with trastuzumab and docetaxel
- Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. β 365 patients were randomized to trastuzumab botidotin (n=182) or trastuzumab emtansine (n=183) after prior trastuzumab and a taxane
π¦ Twitter / π¦ Bluesky
- Risk-adapted neoadjuvant therapy in HER2-positive early breast cancer: the JCO review that clinicians are calling the new standard of care β The review covers de-escalation from docetaxel/paclitaxel, carboplatin, trastuzumab, pertuzumab to taxane plus trastuzumab and pertuzumab, and biomarker-guided chemotherapy-free approaches
- A 2801-patient Japanese analysis quantifies T-DXd interstitial lung disease: 14% incidence, 7.9% of cases fatal, and no benefit from escalating immunosuppression in grade 3-4 β Among 2801 patients, 381 (14%) developed ILD with T-DXd, of which 30 (7.9%) were fatal, and most cases (83%) recovered
- A Nature study finds hypophosphorylated Rb enhances ER transcription, giving CDK4/6 inhibition a built-in proliferative counter-response β A Nature study shows hypophosphorylated Rb unexpectedly enhances ER-mediated transcription, relocating to enhancer regions and reactivating proliferative ER-target genes including CCND1
- New ASCO breast cancer surveillance guideline: risk-stratified follow-up, with no routine tumor markers, metastatic imaging or ctDNA β The new ASCO breast cancer surveillance guideline advises against routine tumor markers, routine metastatic imaging and routine ctDNA, and for appropriate mammography, selective MRI and shared decision-making
- SERENA-4 is negative: camizestrant plus palbociclib fails in the first line, confining oral SERDs to ESR1-mutant disease β Camizestrant did not improve outcomes versus AI when combined with a CDK4/6 inhibitor in the first-line setting, similar to giredestrant
Full details below β
π What's Being Published
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer. β Kleeman Sam O et al., J Clin Oncol
Randomized trial data indicate that carboplatin can be safely omitted from neoadjuvant therapy for most patients with stage II HER2-positive early-stage breast cancer, with comparable pathological complete response rates and reduced toxicity. DESTINY-Breast11 and DESTINY-Breast05 have established neoadjuvant and postneoadjuvant fam-trastuzumab deruxtecan-nxki as new options for high-risk disease, with both indications recently granted FDA approval. The review proposes a risk-adapted framework identifying circulating tumor DNA monitoring and functional imaging as response-adapted strategies.
Clinical bottom line: Neoadjuvant therapy for stage IIβIII HER2-positive breast cancer should be selected by risk rather than given as a uniform TCHP block: carboplatin can be dropped for most stage II disease, while DESTINY-Breast11 and DESTINY-Breast05 define the high-risk T-DXd pathway.
Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis. β Costa de Almeida Luiz Felipe et al., J Natl Cancer Inst
Across 21 trials (18 phase III) evaluating nine ADCs, the pooled ratio of hazard ratios was 0.79 (95% CI, 0.73β0.86), indicating a larger relative effect on PFS than OS; concordant statistical significance between endpoints occurred in 76% of trials, while 24% showed a significant PFS benefit without OS improvement. The largest discrepancies appeared in triple-negative disease (rHR 0.72) and trials allowing crossover (rHR 0.71). The trial-level association between PFS and OS was moderate (RΒ² = 0.62; Ο = 0.67).
Clinical bottom line: PFS systematically overstates the OS effect of ADCs in metastatic breast cancer, so a PFS hazard ratio from an ADC trial should not be read as a survival promise β least of all in triple-negative disease or trials with crossover.
Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial. β Zhang Jin et al., Clin Cancer Res
908 patients were randomized 1:1 to HLX11 (n=454) or EU-pertuzumab (n=454) with trastuzumab and docetaxel; BICR-assessed tpCR was 46.3% with HLX11 versus 45.8% with EU-pertuzumab, meeting equivalence criteria with a relative risk of 1.01 (90% CI 0.90β1.14) and a relative difference of 0.47% (95% CI β5.99%β6.92%). In the adjuvant phase, switching from EU-pertuzumab to HLX11 led to no notable differences in safety, PK, or immunogenicity.
Clinical bottom line: HLX11 is interchangeable with reference pertuzumab in the neoadjuvant HER2-positive setting, including mid-course switching, and should be treated as a cost-reducing substitution rather than a clinical decision.
Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. β Zhang Jian et al., J Clin Oncol
365 patients were randomized to trastuzumab botidotin (n=182) or trastuzumab emtansine (n=183) after prior trastuzumab and a taxane; at a median follow-up of 14.9 months, median PFS was 11.1 versus 4.4 months (HR 0.39, 95% CI 0.30β0.51), and ORR was 76.9% versus 53.0%. Grade β₯3 treatment-emergent adverse events occurred in 127 (69.8%) versus 116 (63.7%) patients; ocular treatment-related adverse events had a high incidence with trastuzumab botidotin, though most events generally recovered or resolved with a protocol-defined algorithm.
Clinical bottom line: Trastuzumab botidotin more than doubles PFS versus T-DM1 in trastuzumab- and taxane-pretreated HER2-positive advanced disease with low pulmonary toxicity, but its ocular toxicity requires a prospective monitoring algorithm and its immature OS leaves its place relative to T-DXd undefined.
Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study. β Zhang J et al., Ann Oncol
162 heavily pretreated patients were enrolled into HER2-positive (n=41), HR+/HER2- (n=75), and TNBC (n=46) groups β 69.8% had β₯3 prior lines of therapy; confirmed ORR was 46.3% in HER2-positive, 37.3% in HR+/HER2-, and 34.8% in TNBC, with median PFS of 5.8, 7.0, and 5.8 months, respectively. Treatment-related adverse events occurred in 99.4% of patients, with grade β₯3 events in 77.8%, primarily neutropenia (55.6%) and anemia (42.0%); two treatment-related deaths occurred and no interstitial lung disease was reported.
Clinical bottom line: Iza-bren delivers roughly one-third to one-half response rates across all three breast subtypes after heavy pretreatment with no ILD signal, but grade β₯3 toxicity in 78% and two treatment-related deaths make myelosuppression, not pneumonitis, the limiting problem for this bispecific ADC.
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer. β Mai Nicholas et al., Clin Cancer Res
Among 272 patients receiving T-DXd for HER2-non-amplified metastatic breast cancer, ERBB2 mutations were found in 20 (7.3%) and were associated with a median rwPFS of 11 versus 6.2 months for wild-type ERBB2; after adjustment for age, treatment line, ER status, and HER2 IHC, ERBB2 mutations were independently associated with longer rwPFS (HR 0.49, 95% CI 0.25β0.96, p=0.038). Nine patients (45%) with ERBB2 mutations had HER2 IHC 0 disease, with no rwPFS difference between HER2 IHC 1β2+ and IHC 0 (HR 1.37, 95% CI 0.35β5.34, p=0.7); in cell lines, common ERBB2 mutants showed faster T-DXd internalization (1.3x to 1.96x) and lower IC50 (0.017 to 0.070 Β΅g/mL versus 2.86 Β΅g/mL) compared to wild-type HER2.
Clinical bottom line: An activating ERBB2 mutation, not HER2 IHC score, identifies HER2-non-amplified metastatic breast cancers that respond to T-DXd β including IHC 0 tumors currently excluded from the label.
π Every paper considered this week, including the ones that didnβt make it β
π£οΈ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
Risk-adapted neoadjuvant therapy in HER2-positive early breast cancer: the JCO review that clinicians are calling the new standard of care
Randomized trial data indicate carboplatin can be safely omitted for most patients with stage II HER2-positive early-stage breast cancer, with comparable pCR rates and reduced toxicity, while biomarker-guided and chemotherapy-free de-escalation strategies are also examined. DESTINY-Breast11 and DESTINY-Breast05 established neoadjuvant and postneoadjuvant fam-trastuzumab deruxtecan-nxki as options for high-risk disease, both recently granted FDA approval. Clinicians characterized the review as the new standard of care and a reason to abandon a one-size-fits-all approach β leaving open the question of what remains of uniform TCHP once carboplatin is dropped for most stage II disease and T-DXd covers the high-risk tier.
Discussed by: @OncBrothers, @Dr_RShatsky
Sources cited: Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Recepto⦠(J Clin Oncol)
A 2801-patient Japanese analysis quantifies T-DXd interstitial lung disease: 14% incidence, 7.9% of cases fatal, and no benefit from escalating immunosuppression in grade 3-4
Among 2801 patients, 381 (14%) developed ILD with T-DXd, of which 30 (7.9%) were fatal; most cases (83%) recovered, and steroids were helpful overall, but neither high-dose steroids nor immunosuppressants improved outcomes in grade 3β4 ILD. In contrast, no interstitial lung disease was reported in the iza-bren phase 1b study across 162 patients. If escalating immunosuppression does not alter outcomes in severe T-DXd ILD, the management burden falls on earlier detection rather than intensified rescue therapy.
Discussed by: @OncBrothers, @stolaney1
Sources cited: Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in⦠(The Oncologist, 2026) · Annals of Oncology
A Nature study finds hypophosphorylated Rb enhances ER transcription, giving CDK4/6 inhibition a built-in proliferative counter-response
A Nature study shows that hypophosphorylated Rb unexpectedly enhances ER-mediated transcription, relocating to enhancer regions and reactivating proliferative ER-target genes including CCND1; CDK4/6 inhibition therefore simultaneously lowers E2F-driven proliferation while triggering an Rb-driven ER transcriptional counter-response that endocrine therapy shuts down. This mechanism was framed both as a biological rationale for combining CDK4/6 inhibition with endocrine therapy and as a potential resistance mechanism. The post-CDK4/6 progression context was linked to the elacestrant plus everolimus arm of ELEVATE (n=73), which reached a median PFS of 8.3 months irrespective of ESR1 or PIK3CA mutations.
Discussed by: @stolaney1, @DFCI_BreastOnc
Sources cited: Rb-driven transcription limits its tumour-suppressive effects in breast cancer (Nature, 2026) · Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative⦠(Clinical Cancer Research, 2026)
New ASCO breast cancer surveillance guideline: risk-stratified follow-up, with no routine tumor markers, metastatic imaging or ctDNA
The new ASCO breast cancer surveillance guideline advises against routine tumor markers, routine metastatic imaging, and routine ctDNA, while supporting appropriate mammography, selective MRI, and shared decision-making; the guiding principle is risk stratification β de-escalating follow-up intensity when appropriate and intensifying it when risk is high. That recommendation sits alongside data showing post-treatment ctDNA to be highly prognostic: 94% of ctDNA-positive patients later developed distant recurrence, with a median 7.9-month lead time and specificity of 99.6%. The tension between a guideline advising against routine ctDNA and assays reporting those performance characteristics is a live debate.
Discussed by: @K_Yadavir, @Dr_ElvinaA
SERENA-4 is negative: camizestrant plus palbociclib fails in the first line, confining oral SERDs to ESR1-mutant disease
Camizestrant plus palbociclib did not significantly improve progression-free survival versus anastrozole plus palbociclib in the first-line SERENA-4 trial β an outcome similar to that seen with giredestrant, which also failed to improve outcomes versus an aromatase inhibitor when combined with a CDK4/6 inhibitor in the first-line setting. The role of camizestrant appears confined to patients with ESR1 mutations, which oncologists characterized as the identifiable sweet spot for oral SERDs in metastatic breast cancer. Whether any rationale remains for moving an oral SERD to the first line ahead of a detected ESR1 mutation is an open question.
Discussed by: @OncBrothers, @OncLive
Sources cited: AstraZeneca press release Β· OncLive
First-line versus later-line ADCs: a JCO commentary and a meta-epidemiologic analysis both argue the trials measure "ever vs never"
A JCO commentary argued that, given study designs and results, none of the first-line ADC trials could formally demonstrate superiority of first-line versus later-line ADC use β instead reflecting the impact of "ever versus never" ADC therapy. That framing is reinforced by the meta-epidemiologic analysis of 21 trials evaluating nine ADCs, in which the pooled ratio of hazard ratios was 0.79 (95% CI, 0.73β0.86), 24% of trials showed a significant PFS benefit without OS improvement, and the trial-level PFSβOS association was only moderate (RΒ² = 0.62). In ASCENT-04, first-line sacituzumab govitecan plus pembrolizumab delayed subsequent treatment in PD-L1-positive advanced TNBC, with a median time to first subsequent therapy of 17.3 versus 9.8 months with chemotherapy plus pembrolizumab β a data point that illustrates the sequencing stakes when PFS readouts may not translate to OS.
Discussed by: @EladSharonMD, @stolaney1
Sources cited: International Breast Cancer Trials and Optimal Sequence of Treatment (Journal of Clinical Oncology, 2026) Β· The ASCO Post
π₯ Top Ranked Tweets
OncoAlert @OncoAlert
RT @OncoAlert: This week's OncoAlert π¨ Newsletter is packed with practice-changing data: REGISTER TO GET IT π https://t.co/NhtuRoIyO3
π¨ THIS WEEK IN ONCOLOGY π¨
Zanidatamab-hrii just posted an improved OS hazard ratio in HER2+ gastroesophageal adenocarcinoma β and that's just the headline. This week's OncoAlert Newsletter also covers:
ποΈ Cemiplimab + fianlimab (dual PD-1/LAG-3 blockade) nearly doubling pCR rates in high-risk breast cancer (I-SPY2)
π« 5-year AEGEAN data on perioperative durvalumab in resectable NSCLC
𧬠DEEPER trial's final word on FOLFOXIRI + cetuximab vs bevacizumab in left-sided mCRC
β’οΈ Radium-223 + enzalutamide accelerating biochemical responses in bone-metastatic mCRPC (PEACE-3)
π¬ TALENTOP: does liver resection after atezolizumab/bevacizumab extend disease control in advanced HCC?
Curated weekly, for colleagues, by colleagues β the biggest trial readouts and practice-changing data across GI, lung, breast, and GU oncology, distilled into a 2-minute read.
@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@JaniceTNBCmets
@montypal
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@tompowles1
@cdanicas
@nataliagandur
@realbowtiedoc
@Onco_Cifu88
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DrRishabhOnco
@PaulJiL
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@BenWestphalen
@CentralParkWMD
@graokane
@amandaNizamMD
@DrVilmaPBarcia
π 4 β€οΈ 30 π 16 π 8,255
OncoAlert @OncoAlert
RT @OncoAlert: The FDA πΊπΈgranted accelerated approval to camizestrant, combined with a CDK4/6 inhibitor, for HR-positive, π§¬HER2-negative advanced #BreastCancer patients who develop ESR1 mutations during aromatase inhibitor and CDK4/6 inhibitor therapy.
https://t.co/M4V91nGQiy
@hoperugo
@JavierCortesMD
@FAndreMD
@matteolambe
@ErikaHamilton9
@DrSGraff
@aftimosp
@BianchiniGP
@ElisaAgostinett
@raalbany
@jamecancerdoc
@Icro_Meattini
@stolaney1
@maryam_lustberg
@LoiSher
@stage4kelly
@to_be_elizabeth
@RebeccaDSing
@double_whammied
@itsnot_pink
@coffeemommy
@FernandoOnco
@JaniceTNBCmets
@TanjaSpanic
@christeeny513
@stage4kelly
@Prof_Nadia_H
@E_de_Azambuja
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@UOzkerim
@DrVilmaPBarcia
@nataliagandur
π 1 β€οΈ 32 π 18 π 9,516
OncoAlert @OncoAlert
RT @jamecancerdoc: FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer @FDAOncology @FDA @OncoAlert https://t.co/3pDOYWrHWY https://t.co/a7sqyRbjk5
π 2 β€οΈ 11 π 7 π 1,599
OncoAlert @OncoAlert
RT @Dr_ElvinaA: FDA accelerated approval for camizestrant + CDK4/6 inhibitor at the emergence of an ESR1 mutation in ctDNA.
For the first time, molecular progression detected in ctDNA can trigger a treatment change. @Larvol @OncoAlert https://t.co/wwsFpzPQcv
π 1 β€οΈ 5 π 4 π 722
Christian Rolfo @ChristianRolfo
RT @isliquidbiopsy: The FDA has granted Accelerated Approval to a new breast cancer therapy, representing another important step forward in the development of biomarker-driven and targeted treatment strategies.
π― The phase III SERENA-6 trial provides important evidence that ctDNA-guided treatment adaptation before radiographic progression can improve outcomes in patients with HR-positive/HER2-negative advanced breast cancer.
π©Έ In patients receiving first-line aromatase inhibitor (AI) plus CDK4/6 inhibitor therapy, serial ctDNA monitoring enabled early detection of emerging ESR1 mutations before clinical or radiographic disease progression.
π― Among 315 patients with ctDNA-detected ESR1 mutations, switching endocrine therapy from an AI to camizestrant while continuing CDK4/6 inhibition significantly improved progression-free survival compared with continuing the initial regimen.
π Median PFS:
Camizestrant switch strategy: 16.0 month
Continued AI-based therapy: 9.2 months
Hazard ratio for progression or death: 0.44 (56% relative risk reduction)
π Why it matters:
SERENA-6 represents a major step toward a new paradigm in precision oncology: moving from waiting for radiographic progression to intervening at the molecular level when resistance emerges.
The study highlights the potential of liquid biopsy not only as a prognostic tool, but as a dynamic biomarker capable of guiding real-time treatment decisions.
@UmbertoMalapel1 @ElJanLe
@drgandara @MJOSESERRANO19
@ChristianRolfo @DrYukselUrun
@LuisRaezMD @ErulEnes
@ReduzziCarol @ddemiguelperez
@PasqualePisapia @Al3ssandroRusso
@ESaldanhaMD @eleonora_nicolo
@DrMirallas
π 2 β€οΈ 41 π 14 π 2,771
Oncology Brothers @OncBrothers
RT @PTarantinoMD: Camizestrant is now approved for 1.5L treatment of patients with HR+ MBC and emergence of ESR1 mutations.
Will you start monitoring for ESR1 mutations with repeat ctDNA testing during 1L treatment?
π 8 β€οΈ 34 π 11 π 21,229
Karamvir Yadav @K_Yadavir
π’ New ASCO Breast Cancer Surveillance Guideline
Not every breast cancer survivor needs the same intensity of follow-up.
Risk-stratify. De-escalate when appropriate. Intensify when risk is high.
β Routine tumor markers
β Routine metastatic imaging
β Routine ctDNA
β Appropriate mammography
β Selective MRI
β Shared decision-making
Less can be moreβwhen evidence and risk support it.
#BreastCancer #ASCO #Oncology #Survivorship @drsarahsam @DFCI_BreastOnc @OncoDailyBreast
π 62 β€οΈ 75 π 42 π 5,593
Dana-Farberβs Breast Oncology Center @DFCI_BreastOnc
RT @DanaFarberNews: The US @FDA has approved camizestrant for advanced breast cancer based on results from the SERENA-6 study. The approval represents a new strategy for treating breast cancer that uses ctDNA to detect emerging resistance to guide the choice of therapy. https://t.co/I47ju9IBra
π 1 β€οΈ 22 π 13 π 1,815
Oncology Learning Network @OncLearnNetwork
π¨ ICYMI: The @US_FDA approved #camizestrant plus a CDK4/6 inhibitor for HR-positive, #HER2-negative advanced #breast cancer, establishing a ctDNA-guided strategy to switch endocrine therapy before disease progression. Learn more: https://t.co/RLMGzydcIT https://t.co/NHF5eZ37lK
π 0 β€οΈ 0 π 0 π 105
Cancer Survivors Club π @thecancersurvivorsclub.com
A new approach to treating advanced breast cancer. The FDA has approved Etcamah after a blood test detects an ESR1 resistance mutation, allowing treatment to change before scans show the cancer progressing.
www.fda.gov/news-events/...
#BreastCancer #CancerTreatment #PrecisionMedicine #TCSC
π 0 β€οΈ 0 π 0 π 0
Cancer Survivors Club π @thecancersurvivorsclub.com
A first for breast cancer treatment. The FDA has approved camizestrant for certain patients, using a blood test to detect treatment resistance before it appears on scans.
www.beckersoncology.com/pharmacy/fda...
#BreastCancer #CancerResearch #TCSC
π 0 β€οΈ 1 π 1 π 0
MedChemExpress @medchemexpress.bsky.social
π―#FDA approves #camizestrant (#Etcamah, AstraZeneca) + a CDK4/6 inhibitor for #ESR1-mutated HR+/HER2β advanced or metastatic breast cancer, using ctDNA to detect emerging resistance and guide a targeted treatment switch.
#FDAApproval #BreastCancer #ctDNA #PrecisionMedicine #Oncology
π 0 β€οΈ 0 π 0 π 0
Cancer Survivors Club π @thecancersurvivorsclub.com
A first for breast cancer treatment. The FDA has approved camizestrant for certain advanced breast cancers, guided by a blood test that can detect treatment resistance before it appears on scans.
www.bcrf.org/blog/fda-app...
#BreastCancer #CancerResearch #TCSC
π 0 β€οΈ 0 π 0 π 0
pharmaphorum @pharmaphorum.bsky.social
The #FDA has gone against the advice of its own expert advisors and approved #AstraZeneca's #Etcamah as a frontline treatment for #breastcancer.
pharmaphorum.com/news/fda-ove...
π 0 β€οΈ 0 π 0 π 0
OncoAlert @OncoAlert
RT @oncologytube: SERENA-6: switching to camizestrant on emergent ESR1 ctDNA before imaging progression gave PFS 16.0 vs 9.2 months (HR 0.44). Our full writeup of the accelerated approval: https://t.co/4ScDMTP5QO
π 1 β€οΈ 11 π 3 π 1,932
π§ͺ Newly Recruiting Trials
2 trials (1 phase I, 1 device/procedure) opened this week, testing letrozole SIE (quarterly injectable) and ProSense cryoablation system β see them all on the website β
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.
☕ Not funded by anyone — no sponsors, no pharma. Buy me a coffee if it's useful.